TSC2 and acute myeloid leukemia: Median OS was 204.9 months (95% CI: 81.6–not reached) for all the patients in the study, 81.6 months (95% CI: 80.8–not reached) for those with malignant PEComa, and 216.5 months (95% CI: not reached) for those with AML and LAM combined (Supplementary Table S6; Supplementary Fig. S4A).